Neurotech’s ENCELTO™ (revakinagene taroretcel-lwey) Approved by the FDA for the Treatment of Adults with Idiopathic Macular Telangiectasia Type 2 (MacTel)

Name: Neurotech’s ENCELTO™ (revakinagene taroretcel-lwey) Approved by the FDA for the Treatment of Adults with Idiopathic Macular Telangiectasia Type 2 (MacTel) | neurotech
Published: 2025-03-06T14:58:05+00:00

Home » Neurotech’s ENCELTO™ (revakinagene taroretcel-lwey) Approved by the FDA for the Treatment of Adults with Idiopathic Macular Telangiectasia Type 2 (MacTel)

Press Release – Neurotech receives approval for ENCELTO (revakinagene taroretcel-lwey)

Read Full Press Release Here

⇧